You can add AbbVie and Allergan’s $63 billion merger to the list of plans potentially disrupted by Covid-19. The Federal Trade Commission said that it may need to offer extensions on certain cases because coronavirus-related disruptions may make it difficult for companies to make documents and witnesses available, Bloomberg reported. That could mean a sudden roadblock just … Continue reading Covid-19 could throw final hurdle into AbbVie and Allergan’s massive merger